Chronic inflammatory demyelinating polyradiculoneuropathy is a rare autoimmune-related condition that affects nerve signaling ...
Investor's Business Daily on MSN
Dianthus Therapeutics has appreciated 12-fold over two years. What's going on?
Dianthus Therapeutics stock shot higher Monday after the company said it would advance its experimental CIDP treatment.
Earlier this week, Dianthus Therapeutics completed an upsized follow-on offering raising about US$625.00 million in common stock and pre-funded warrants, shortly after reporting wider 2025 losses and ...
Shares of Dianthus Therapeutics rose after the company reached an early decision to move ahead with its phase 3 trial for Chronic Inflammatory Demyelinating Polyneuropathy, an autoimmune disorder. The ...
Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants ...
Early GO decision reached in CAPTIVATE ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned ...
Dianthus Therapeutics Inc. DNTH shares are up during Monday’s premarket session following an early GO decision announced by ...
Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today ...
The FDA on March 16 approved CSL Behring’s drug Hizentra to treat chronic inflammatory demyelinating polyneuropathy. Hizentra is the first subcutaneous immunoglobulin approved to treat CIDP, a rare ...
CEO Tim Van Hauwermeiren emphasized 2024 as a "phenomenal year," highlighted by expanding the reach of VYVGART to over 10,000 patients globally across three approved indications. He noted the ...
But you can decrease CIDP anxiety with techniques to stay grounded when you’re dreading an appointment or the return of symptoms. The news that you have a life-changing chronic illness can feel ...
WAYNE, Pennsylvania (WPVI) -- One step at a time, those who are diagnosed with rare neuropathic conditions such as GBS or CIDP prove it's possible to get back on their feet. A great place to see their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results